2024 in Review: Are Drug Access Agreement Trends Going the Right Way?

As drug prices and the cost of care continue to rise worldwide, it’s more important than ever to bring therapies to patients in a cost-effective way. We believe that innovative reimbursement agreements will continue to provide a vital gateway to patient access in coming years. This year we monitored publicly available agreements across the US, Europe and many emerging markets.

Hear from Industry expert, Daniel Parle, as he shares findings and insights from the 2024 Report. We’ll discuss this year’s data from Lyfegen’s public access agreements Library, which reflects a significant shift toward innovative reimbursement agreements that support the accessibility of high-cost therapies. We will also share how data and AI can help to improve drug contract negotiations and enable accelerated access.

‍